{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T11:37:18Z","timestamp":1793619438669,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hetzler Foundation (https:\/\/hetzler-stiftung.de\/), no Grant Reference Number available"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Although alcohol use disorder (AUD) is highly prevalent, only a few medications are approved for its treatment leaving much room for improvement. Cannabidiol (CBD) might be a particularly promising candidate, with preclinical data suggesting that CBD is effective in targeting AUD symptoms and disease processes that drive alcohol use and relapse, due to its anti-craving, stress-reducing, and anti-compulsive effects. Here we report data from the double-blind randomized controlled ICONIC trial that compared the effects of a single dose of 800\u2009mg cannabidiol against placebo (PLC) in N\u2009=\u200928 individuals with AUD. Cue-induced nucleus accumbens (NAc) activation, alcohol craving during a combined stress- and alcohol cue exposure session, as well as craving during an fMRI alcohol cue-reactivity task and CBD plasma levels served as outcomes. Individuals receiving CBD showed lower bilateral cue-induced NAc activation (<jats:italic>t<\/jats:italic>\n            <jats:sub>\n              <jats:italic>left<\/jats:italic>_NAc(23)<\/jats:sub>\u2009=\u20094.906, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, d\u2009=\u20091.15; <jats:italic>t<\/jats:italic>\n            <jats:sub>right_NAc (23)<\/jats:sub>\u2009=\u20094.873, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, d\u2009=\u20091.13) and reported significantly lower alcohol craving after a combined stress- and alcohol cue exposure session (<jats:italic>F<\/jats:italic>\n            <jats:sub>group(1,26)<\/jats:sub>\u2009=\u20094.516, <jats:italic>p<\/jats:italic>\u2009=\u20090.043, eta<jats:sup>2<\/jats:sup>\u2009=\u20090.15) and during the fMRI cue-reactivity task (<jats:italic>F<\/jats:italic>\n            <jats:sub>group(1,24)<\/jats:sub>\u2009=\u20096.665, <jats:italic>p<\/jats:italic>\u2009=\u20090.015, eta<jats:sup>2<\/jats:sup>\u2009=\u20090.23). CBD levels were significantly higher in the CBD group (<jats:italic>t<\/jats:italic>\n            <jats:sub>(25)<\/jats:sub>\u2009=\u20093.808, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, d\u2009=\u20091.47) and showed a significant negative association with alcohol craving during the cue exposure experiment (<jats:italic>r<\/jats:italic>\u2009=\u2009\u22120.394, <jats:italic>p<\/jats:italic>\n            <jats:sub>FDR<\/jats:sub>\u2009=\u20090.030) and during fMRI (<jats:italic>r<\/jats:italic>\u2009=\u2009\u22120.389, <jats:italic>p<\/jats:italic>\n            <jats:sub>FDR<\/jats:sub>\u2009=\u20090.030), and with left and right NAc activation (<jats:italic>r<\/jats:italic>\n            <jats:sub>left<\/jats:sub>_<jats:sub>NAc<\/jats:sub>\u2009=\u2009\u22120.459, <jats:italic>p<\/jats:italic>\n            <jats:sub>FDR<\/jats:sub>\u2009=\u20090.030; <jats:italic>r<\/jats:italic>\n            <jats:sub>right<\/jats:sub>_<jats:sub>NAc<\/jats:sub>\u2009=\u2009\u22120.405, <jats:italic>p<\/jats:italic>\n            <jats:sub>FDR<\/jats:sub>\u2009=\u20090.030). CBD\u2019s capacity to reduce stress- and cue-induced alcohol craving and to normalize NAc activation \u2013 a region critical to the pathophysiology of AUD \u2013 contribute to understanding the neurobiological basis of its clinical effects and support its potential as a treatment option for AUD. Clinical Trials Registry: DRKS00029993.<\/jats:p>","DOI":"10.1038\/s41380-024-02869-y","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T14:36:03Z","timestamp":1734014163000},"page":"2612-2619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Acute cannabidiol administration reduces alcohol craving and cue-induced nucleus accumbens activation in individuals with alcohol use disorder: the double-blind randomized controlled ICONIC trial"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9122-5197","authenticated-orcid":false,"given":"Sina","family":"Zimmermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Teetzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joscha","family":"Bae\u00dfler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Schreckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2863-8284","authenticated-orcid":false,"given":"Judith","family":"Zaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlen","family":"Pfisterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Stenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5962-019X","authenticated-orcid":false,"given":"Patrick","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"2869_CR1","unstructured":"Global status report on alcohol and health 2018. https:\/\/www.who.int\/substance_abuse\/publications\/global_alcohol_report\/en\/."},{"key":"2869_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.drugalcdep.2016.08.625","volume":"168","author":"MJ Fleury","year":"2016","unstructured":"Fleury MJ, Djouini A, Hu\u1ef3nh C, Tremblay J, Ferland F, M\u00e9nard JM, et al. Remission from substance use disorders: a systematic review and meta-analysis. Drug Alcohol Depend. 2016;168:293\u2013306.","journal-title":"Drug Alcohol Depend"},{"key":"2869_CR3","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1038\/s41386-018-0050-8","volume":"43","author":"G Gonzalez-Cuevas","year":"2018","unstructured":"Gonzalez-Cuevas G, Martin-Fardon R, Kerr TM, Stouffer DG, Parsons LH, Hammell DC, et al. Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle. Neuropsychopharmacology. 2018;43:2036\u201345.","journal-title":"Neuropsychopharmacology"},{"key":"2869_CR4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/adb.12495","volume":"23","author":"A Viudez-Mart\u00ednez","year":"2018","unstructured":"Viudez-Mart\u00ednez A, Garc\u00eda-Guti\u00e9rrez MS, Navarr\u00f3n CM, Morales-Calero MI, Navarrete F, Torres-Su\u00e1rez AI, et al. Cannabidiol reduces ethanol consumption, motivation and relapse in mice. Addict Biol. 2018;23:154\u201364.","journal-title":"Addict Biol"},{"key":"2869_CR5","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1111\/bph.14380","volume":"175","author":"A Viudez-Mart\u00ednez","year":"2018","unstructured":"Viudez-Mart\u00ednez A, Garc\u00eda-Guti\u00e9rrez MS, Fraguas-S\u00e1nchez AI, Torres-Su\u00e1rez AI, Manzanares J. Effects of cannabidiol plus naltrexone on motivation and ethanol consumption. Br J Pharmacol. 2018;175:3369\u201378.","journal-title":"Br J Pharmacol"},{"key":"2869_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1037\/pha0000272","volume":"27","author":"CN Nona","year":"2019","unstructured":"Nona CN, Hendershot CS, Le Foll B. Effects of cannabidiol on alcohol-related outcomes: a review of preclinical and human research. Exp Clin Psychopharmacol. 2019;27:359\u201369.","journal-title":"Exp Clin Psychopharmacol"},{"key":"2869_CR7","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/acer.13964","volume":"43","author":"J Turna","year":"2019","unstructured":"Turna J, Syan SK, Frey BN, Rush B, Costello MJ, Weiss M, et al. Cannabidiol as a novel candidate alcohol use disorder pharmacotherapy: a systematic review. Alcohol Clin Exp Res. 2019;43:550\u201363.","journal-title":"Alcohol Clin Exp Res"},{"key":"2869_CR8","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","volume":"176","author":"YL Hurd","year":"2019","unstructured":"Hurd YL, Spriggs S, Alishayev J, Winkel G, Gurgov K, Kudrich C, et al. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry. 2019;176:911\u201322.","journal-title":"Am J Psychiatry"},{"key":"2869_CR9","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s13311-015-0373-7","volume":"12","author":"YL Hurd","year":"2015","unstructured":"Hurd YL, Yoon M, Manini AF, Hernandez S, Olmedo R, Ostman M, et al. Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage. Neurotherapeutics. 2015;12:807\u201315.","journal-title":"Neurotherapeutics"},{"key":"2869_CR10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1037\/adb0000706","volume":"35","author":"HC Karoly","year":"2021","unstructured":"Karoly HC, Mueller RL, Andrade CC, Hutchison KE. THC and CBD effects on alcohol use among alcohol and cannabis co-users. Psychol Addict Behav. 2021;35:749\u201359.","journal-title":"Psychol Addict Behav"},{"key":"2869_CR11","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S2215-0366(20)30290-X","volume":"7","author":"TP Freeman","year":"2020","unstructured":"Freeman TP, Hindocha C, Baio G, Shaban NDC, Thomas EM, Astbury D, et al. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry. 2020;7:865\u201374.","journal-title":"Lancet Psychiatry"},{"key":"2869_CR12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/adb.12150","volume":"20","author":"LE Kwako","year":"2015","unstructured":"Kwako LE, Schwandt ML, Sells JR, Ramchandani VA, Hommer DW, George DT, et al. Methods for inducing alcohol craving in individuals with co-morbid alcohol dependence and posttraumatic stress disorder: behavioral and physiological outcomes. Addict Biol. 2015;20:733\u201346.","journal-title":"Addict Biol"},{"key":"2869_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.biopsych.2023.08.024","volume":"95","author":"P Bach","year":"2024","unstructured":"Bach P, Zaiser J, Zimmermann S, Gessner T, Hoffmann S, Gerhardt S, et al. Stress-induced sensitization of insula activation predicts alcohol craving and alcohol use in alcohol use disorder. Biol Psychiatry. 2024;95:245\u201355.","journal-title":"Biol Psychiatry"},{"key":"2869_CR14","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/j.1369-1600.2011.00352.x","volume":"17","author":"SLS Vollstadt-Klein","year":"2012","unstructured":"Vollstadt-Klein SLS, Richter A, Kirsch M, Bach P, von der Goltz C, Hermann D, et al. Validating incentive salience with functional magnetic resonance imaging: association between mesolimbic cue reactivity and attentional bias in alcohol-dependent patients. Addict Biol. 2012;17:807\u201316.","journal-title":"Addict Biol"},{"key":"2869_CR15","doi-asserted-by":"crossref","unstructured":"Bach P, Hill H, Reinhard I, G\u00e4deke T, Kiefer F, Lem\u00e9nager T. Reliability of the fMRI-based assessment of self-evaluation in individuals with internet gaming disorder. Eur Arch Psychiatry Clin Neurosci. 2021;272:1119\u201334.","DOI":"10.1007\/s00406-021-01307-2"},{"key":"2869_CR16","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1001\/archneur.64.11.1575","volume":"64","author":"ND Volkow","year":"2007","unstructured":"Volkow ND, Fowler JS, Wang GJ, Swanson JM, Telang F. Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol. 2007;64:1575\u20139.","journal-title":"Arch Neurol"},{"key":"2869_CR17","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1016\/j.neuroimage.2009.10.088","volume":"49","author":"ND Volkow","year":"2010","unstructured":"Volkow ND, Fowler JS, Wang GJ, Telang F, Logan J, Jayne M, et al. Cognitive control of drug craving inhibits brain reward regions in cocaine abusers. Neuroimage. 2010;49:2536\u201343.","journal-title":"Neuroimage"},{"key":"2869_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1369-1600.2012.00464.x","volume":"18","author":"JP Schacht","year":"2013","unstructured":"Schacht JP, Anton RF, Myrick H. Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review. Addict Biol. 2013;18:121\u201333.","journal-title":"Addict Biol"},{"key":"2869_CR19","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.euroneuro.2015.04.013","volume":"25","author":"P Bach","year":"2015","unstructured":"Bach P, Vollst\u00e4dt-Klein S, Kirsch M, Hoffmann S, Jorde A, Frank J, et al. Increased mesolimbic cue-reactivity in carriers of the mu-opioid-receptor gene OPRM1 A118G polymorphism predicts drinking outcome: a functional imaging study in alcohol dependent subjects. Eur Neuropsychopharmacol. 2015;25:1128\u201335.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2869_CR20","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00406-021-01259-7","volume":"271","author":"P Bach","year":"2021","unstructured":"Bach P, Weil G, Pompili E, Hoffmann S, Hermann D, Vollstadt-Klein S, et al. FMRI-based prediction of naltrexone response in alcohol use disorder: a replication study. Eur Arch Psychiatry Clin Neurosci. 2021;271:915\u201327.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2869_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40429-020-00326-8","volume":"7","author":"DJ Sholler","year":"2020","unstructured":"Sholler DJ, Schoene L, Spindle TR. Therapeutic Efficacy of Cannabidiol (CBD): a review of the evidence from clinical trials and human laboratory studies. Curr Addict Rep. 2020;7:405\u201312.","journal-title":"Curr Addict Rep"},{"key":"2869_CR22","doi-asserted-by":"crossref","unstructured":"Millar SA, Stone NL, Yates AS, O\u2019Sullivan SE. A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol. 2018;9:1365.","DOI":"10.3389\/fphar.2018.01365"},{"key":"2869_CR23","doi-asserted-by":"crossref","unstructured":"Calapai F, Cardia L, Sorbara EE, Navarra M, Gangemi S, Calapai G, et al. Cannabinoids, blood-brain barrier, and brain disposition. Pharmaceutics. 2020;12:265.","DOI":"10.3390\/pharmaceutics12030265"},{"key":"2869_CR24","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/j.1530-0277.1995.tb01554.x","volume":"19","author":"MJ Bohn","year":"1995","unstructured":"Bohn MJ, Krahn DD, Staehler BA. Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res. 1995;19:600\u20136.","journal-title":"Alcohol Clin Exp Res"},{"key":"2869_CR25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000119004","volume":"28","author":"C Kirschbaum","year":"1993","unstructured":"Kirschbaum C, Pirke K-M, Hellhammer DH. The \u2018Trier Social Stress Test\u2019\u2013a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology. 1993;28:76\u201381.","journal-title":"Neuropsychobiology"},{"key":"2869_CR26","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/j.1460-9568.2010.07590.x","volume":"33","author":"S K\u00fchn","year":"2011","unstructured":"K\u00fchn S, Gallinat J. Common biology of craving across legal and illegal drugs \u2013 a quantitative meta-analysis of cue-reactivity brain response. Eur J Neurosci. 2011;33:1318\u201326.","journal-title":"Eur J Neurosci"},{"key":"2869_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12717","volume":"25","author":"P Bach","year":"2020","unstructured":"Bach P, Weil G, Pompili E, Hoffmann S, Hermann D, Vollstadt-Klein S, et al. Incubation of neural alcohol cue reactivity after withdrawal and its blockade by naltrexone. Addict Biol. 2020;25:e12717.","journal-title":"Addict Biol"},{"key":"2869_CR28","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1038\/npp.2017.74","volume":"42","author":"JP Schacht","year":"2017","unstructured":"Schacht JP, Randall PK, Latham PK, Voronin KE, Book SW, Myrick H, et al. Predictors of naltrexone response in a randomized trial: reward-related brain activation, OPRM1 genotype, and smoking status. Neuropsychopharmacology. 2017;42:2640\u201353.","journal-title":"Neuropsychopharmacology"},{"key":"2869_CR29","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2018.2309","volume":"75","author":"S Bhattacharyya","year":"2018","unstructured":"Bhattacharyya S, Wilson R, Appiah-Kusi E, O\u2019Neill A, Brammer M, Perez J, et al. Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial. JAMA Psychiatry. 2018;75:1107\u201317.","journal-title":"JAMA Psychiatry"},{"key":"2869_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-0862-2","volume":"10","author":"C Davies","year":"2020","unstructured":"Davies C, Wilson R, Appiah-Kusi E, Blest-Hopley G, Brammer M, Perez J, et al. A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis. Transl Psychiatry. 2020;10:311.","journal-title":"Transl Psychiatry"},{"key":"2869_CR31","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1017\/S0033291719003519","volume":"51","author":"L Annibale","year":"2021","unstructured":"Annibale L, Bhattacharyya S, Blest-Hopley G, Brammer M, Colizzi M, Giampietro V, et al. Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis. Psychol Med. 2021;51:596\u2013606.","journal-title":"Psychol Med"},{"key":"2869_CR32","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0165-0173(93)90013-P","volume":"18","author":"TE Robinson","year":"1993","unstructured":"Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev. 1993;18:247\u201391.","journal-title":"Brain Res Brain Res Rev"},{"key":"2869_CR33","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1111\/add.14243","volume":"113","author":"C Hindocha","year":"2018","unstructured":"Hindocha C, Freeman TP, Grabski M, Stroud JB, Crudgington H, Davies AC, et al. Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal. Addiction. 2018;113:1696\u2013705.","journal-title":"Addiction"},{"key":"2869_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0534-2","volume":"9","author":"R Wilson","year":"2019","unstructured":"Wilson R, Bossong MG, Appiah-Kusi E, Petros N, Brammer M, Perez J, et al. Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis. Transl Psychiatry. 2019;9:203.","journal-title":"Transl Psychiatry"},{"key":"2869_CR35","doi-asserted-by":"publisher","first-page":"4732","DOI":"10.1017\/S0033291722001672","volume":"53","author":"B Gunasekera","year":"2023","unstructured":"Gunasekera B, Wilson R, O\u2019Neill A, Blest-Hopley G, O\u2019Daly O, Bhattacharyya S. Cannabidiol attenuates insular activity during motivational salience processing in patients with early psychosis. Psychol Med. 2023;53:4732\u201341.","journal-title":"Psychol Med"},{"key":"2869_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.109828","volume":"245","author":"C Gauld","year":"2023","unstructured":"Gauld C, Baillet E, Micoulaud-Franchi J-A, Kervran C, Serre F, Auriacombe M. The centrality of craving in network analysis of five substance use disorders. Drug Alcohol Depend. 2023;245:109828.","journal-title":"Drug Alcohol Depend"},{"key":"2869_CR37","doi-asserted-by":"publisher","first-page":"e2337192","DOI":"10.1001\/jamanetworkopen.2023.37192","volume":"6","author":"AP Miller","year":"2023","unstructured":"Miller AP, Kuo SIC, Johnson EC, Tillman R, Brislin SJ, Dick DM, et al. Diagnostic criteria for identifying individuals at high risk of progression from mild or moderate to severe alcohol use disorder. JAMA Netw Open. 2023;6:e2337192.","journal-title":"JAMA Netw Open"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02869-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02869-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02869-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T09:57:44Z","timestamp":1747735064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02869-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2869"],"URL":"https:\/\/doi.org\/10.1038\/s41380-024-02869-y","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]},"assertion":[{"value":"23 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors PB, SZ, AT, JB, LS, JZ, MP, and MS report no biomedical financial interests or potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This trial was approved by the local ethics committee of the medical faculty Mannheim of the University of Heidelberg (2022-579-AF 5) and preregistered (German clinical trials database: DRKS00029993). Written informed consent was obtained from all participants and the trial was conducted in accordance to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}